Cathy Bradley
Concepts (505)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Employment | 41 | 2025 | 180 | 10.250 |
Why?
| | Neoplasms | 74 | 2026 | 2954 | 9.670 |
Why?
| | Medicaid | 38 | 2026 | 477 | 7.530 |
Why?
| | Cancer Survivors | 18 | 2025 | 348 | 5.600 |
Why?
| | Breast Neoplasms | 49 | 2024 | 2418 | 5.060 |
Why?
| | Medicare | 38 | 2026 | 920 | 4.430 |
Why?
| | Insurance Coverage | 22 | 2024 | 248 | 4.180 |
Why?
| | Cost of Illness | 15 | 2025 | 323 | 3.870 |
Why?
| | Insurance, Health | 21 | 2026 | 318 | 3.650 |
Why?
| | SEER Program | 22 | 2024 | 233 | 3.040 |
Why?
| | Poverty | 13 | 2022 | 530 | 2.740 |
Why?
| | Medically Uninsured | 12 | 2020 | 134 | 2.400 |
Why?
| | United States | 100 | 2026 | 16136 | 2.330 |
Why?
| | Healthcare Disparities | 14 | 2020 | 733 | 2.300 |
Why?
| | Colorectal Neoplasms | 16 | 2025 | 874 | 2.280 |
Why?
| | Uterine Cervical Neoplasms | 7 | 2020 | 269 | 2.190 |
Why?
| | Health Services Accessibility | 18 | 2024 | 1107 | 2.150 |
Why?
| | Survivors | 17 | 2022 | 526 | 2.030 |
Why?
| | Early Detection of Cancer | 11 | 2026 | 506 | 2.030 |
Why?
| | Medical Oncology | 6 | 2024 | 345 | 1.920 |
Why?
| | Registries | 33 | 2026 | 2400 | 1.810 |
Why?
| | Health Benefit Plans, Employee | 5 | 2022 | 25 | 1.780 |
Why?
| | Health Care Costs | 14 | 2024 | 423 | 1.740 |
Why?
| | Humans | 208 | 2026 | 146342 | 1.730 |
Why?
| | Antineoplastic Agents | 9 | 2025 | 2219 | 1.730 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2025 | 1195 | 1.690 |
Why?
| | Health Expenditures | 10 | 2026 | 198 | 1.560 |
Why?
| | Survivorship | 4 | 2022 | 62 | 1.530 |
Why?
| | Drug Costs | 4 | 2025 | 116 | 1.480 |
Why?
| | Health Care Reform | 4 | 2021 | 110 | 1.410 |
Why?
| | Lung Neoplasms | 11 | 2025 | 2675 | 1.390 |
Why?
| | Caregivers | 6 | 2023 | 1080 | 1.360 |
Why?
| | Aged | 80 | 2026 | 26432 | 1.330 |
Why?
| | Female | 133 | 2026 | 79499 | 1.270 |
Why?
| | Colonic Neoplasms | 5 | 2016 | 259 | 1.230 |
Why?
| | Socioeconomic Factors | 21 | 2026 | 1327 | 1.170 |
Why?
| | Policy | 4 | 2024 | 147 | 1.160 |
Why?
| | Prostatic Neoplasms | 11 | 2022 | 972 | 1.160 |
Why?
| | Research | 6 | 2022 | 421 | 1.150 |
Why?
| | Middle Aged | 80 | 2026 | 36619 | 1.140 |
Why?
| | Mental Health | 4 | 2023 | 779 | 1.140 |
Why?
| | Michigan | 24 | 2015 | 203 | 1.100 |
Why?
| | Prescription Drugs | 2 | 2023 | 110 | 1.080 |
Why?
| | Income | 8 | 2024 | 206 | 1.060 |
Why?
| | Male | 102 | 2026 | 73396 | 1.060 |
Why?
| | Aged, 80 and over | 38 | 2025 | 8391 | 1.050 |
Why?
| | Efficiency | 7 | 2016 | 102 | 1.040 |
Why?
| | Neoplasm Staging | 17 | 2022 | 1488 | 1.020 |
Why?
| | Health Status | 10 | 2013 | 827 | 1.000 |
Why?
| | Medical Record Linkage | 2 | 2021 | 68 | 0.960 |
Why?
| | Health Status Disparities | 2 | 2023 | 322 | 0.950 |
Why?
| | Adult | 70 | 2026 | 41087 | 0.940 |
Why?
| | Papanicolaou Test | 2 | 2017 | 35 | 0.940 |
Why?
| | Primary Health Care | 6 | 2023 | 1776 | 0.870 |
Why?
| | Motivation | 2 | 2020 | 605 | 0.860 |
Why?
| | Cost Sharing | 2 | 2026 | 23 | 0.840 |
Why?
| | Occupational Medicine | 1 | 2024 | 13 | 0.830 |
Why?
| | Safety-net Providers | 3 | 2017 | 133 | 0.830 |
Why?
| | Cancer Care Facilities | 4 | 2024 | 48 | 0.830 |
Why?
| | Medicare Part C | 1 | 2025 | 39 | 0.820 |
Why?
| | Patient Acceptance of Health Care | 4 | 2018 | 881 | 0.800 |
Why?
| | Eligibility Determination | 5 | 2018 | 73 | 0.780 |
Why?
| | Comorbidity | 12 | 2019 | 1665 | 0.770 |
Why?
| | Communication | 3 | 2024 | 980 | 0.760 |
Why?
| | Quality of Life | 8 | 2023 | 3200 | 0.760 |
Why?
| | Colonoscopy | 4 | 2019 | 257 | 0.740 |
Why?
| | Return to Work | 4 | 2022 | 21 | 0.730 |
Why?
| | Absenteeism | 4 | 2013 | 51 | 0.720 |
Why?
| | Mass Screening | 10 | 2022 | 1307 | 0.700 |
Why?
| | Virginia | 7 | 2018 | 57 | 0.690 |
Why?
| | Occupational Health | 1 | 2024 | 212 | 0.670 |
Why?
| | Focus Groups | 1 | 2024 | 588 | 0.670 |
Why?
| | Workplace | 4 | 2021 | 268 | 0.660 |
Why?
| | Medication Adherence | 2 | 2023 | 535 | 0.660 |
Why?
| | Young Adult | 27 | 2026 | 14330 | 0.650 |
Why?
| | Mammography | 5 | 2024 | 175 | 0.630 |
Why?
| | Immunotherapy | 1 | 2025 | 671 | 0.610 |
Why?
| | Models, Economic | 2 | 2011 | 63 | 0.600 |
Why?
| | Health Equity | 1 | 2022 | 139 | 0.590 |
Why?
| | Information Dissemination | 1 | 2022 | 226 | 0.590 |
Why?
| | Insurance Claim Review | 3 | 2026 | 87 | 0.590 |
Why?
| | Public Health | 1 | 2024 | 574 | 0.570 |
Why?
| | Chemotherapy, Adjuvant | 7 | 2023 | 429 | 0.570 |
Why?
| | Preventive Health Services | 5 | 2023 | 154 | 0.570 |
Why?
| | Perioperative Care | 1 | 2021 | 235 | 0.560 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 23 | 0.560 |
Why?
| | Retirement | 5 | 2022 | 35 | 0.560 |
Why?
| | Health Facilities | 1 | 2019 | 85 | 0.550 |
Why?
| | Spouses | 3 | 2017 | 107 | 0.540 |
Why?
| | Cost-Benefit Analysis | 9 | 2024 | 640 | 0.530 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 340 | 0.530 |
Why?
| | Quality Indicators, Health Care | 1 | 2020 | 343 | 0.530 |
Why?
| | Survival Analysis | 10 | 2019 | 1378 | 0.520 |
Why?
| | Reimbursement, Incentive | 1 | 2017 | 44 | 0.500 |
Why?
| | Healthy People Programs | 1 | 2016 | 7 | 0.480 |
Why?
| | Occupational Health Services | 2 | 2016 | 36 | 0.480 |
Why?
| | Bevacizumab | 1 | 2017 | 169 | 0.470 |
Why?
| | Logistic Models | 13 | 2023 | 2126 | 0.470 |
Why?
| | Job Satisfaction | 3 | 2013 | 236 | 0.460 |
Why?
| | Job Description | 2 | 2013 | 10 | 0.460 |
Why?
| | Massachusetts | 4 | 2021 | 178 | 0.450 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2023 | 220 | 0.450 |
Why?
| | Outpatients | 1 | 2019 | 440 | 0.450 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 704 | 0.440 |
Why?
| | Length of Stay | 6 | 2012 | 1358 | 0.430 |
Why?
| | Databases, Factual | 9 | 2026 | 1493 | 0.430 |
Why?
| | Chronic Pain | 1 | 2019 | 304 | 0.430 |
Why?
| | State Government | 3 | 2014 | 45 | 0.420 |
Why?
| | Rectal Neoplasms | 1 | 2016 | 160 | 0.420 |
Why?
| | Fee-for-Service Plans | 4 | 2023 | 98 | 0.420 |
Why?
| | Vaginal Smears | 1 | 2014 | 54 | 0.420 |
Why?
| | Nursing Homes | 4 | 2013 | 171 | 0.420 |
Why?
| | Risk Factors | 17 | 2026 | 10921 | 0.410 |
Why?
| | Longitudinal Studies | 11 | 2022 | 3017 | 0.400 |
Why?
| | Mouth Neoplasms | 3 | 2019 | 88 | 0.400 |
Why?
| | Health Services Research | 4 | 2010 | 390 | 0.400 |
Why?
| | Emergency Treatment | 1 | 2015 | 122 | 0.400 |
Why?
| | General Practice | 1 | 2014 | 32 | 0.400 |
Why?
| | Sick Leave | 2 | 2019 | 16 | 0.390 |
Why?
| | Delivery of Health Care | 5 | 2024 | 947 | 0.390 |
Why?
| | Cross-Sectional Studies | 13 | 2023 | 5899 | 0.380 |
Why?
| | Behavioral Risk Factor Surveillance System | 4 | 2017 | 55 | 0.370 |
Why?
| | Sickness Impact Profile | 1 | 2013 | 67 | 0.370 |
Why?
| | Colorado | 6 | 2026 | 4595 | 0.370 |
Why?
| | Health Personnel | 3 | 2022 | 754 | 0.370 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2015 | 2623 | 0.360 |
Why?
| | Marital Status | 3 | 2007 | 47 | 0.360 |
Why?
| | Value of Life | 2 | 2008 | 18 | 0.360 |
Why?
| | Homes for the Aged | 2 | 2013 | 30 | 0.350 |
Why?
| | Work | 3 | 2010 | 23 | 0.350 |
Why?
| | Cohort Studies | 10 | 2025 | 6077 | 0.350 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1998 | 0.340 |
Why?
| | Age Factors | 11 | 2022 | 3347 | 0.340 |
Why?
| | Survival Rate | 7 | 2020 | 2092 | 0.340 |
Why?
| | Neoplasm Metastasis | 3 | 2020 | 693 | 0.330 |
Why?
| | Health Services | 1 | 2012 | 112 | 0.330 |
Why?
| | Periodicals as Topic | 2 | 2023 | 214 | 0.320 |
Why?
| | Patient Protection and Affordable Care Act | 3 | 2024 | 105 | 0.320 |
Why?
| | Hypoglycemia | 1 | 2015 | 490 | 0.320 |
Why?
| | Social Class | 4 | 2022 | 260 | 0.320 |
Why?
| | Physician Self-Referral | 1 | 2010 | 1 | 0.320 |
Why?
| | Quality Improvement | 2 | 2018 | 1354 | 0.310 |
Why?
| | Intestinal Perforation | 3 | 2016 | 46 | 0.310 |
Why?
| | Surgical Procedures, Operative | 2 | 2012 | 307 | 0.300 |
Why?
| | Models, Econometric | 6 | 2017 | 35 | 0.300 |
Why?
| | Financing, Personal | 2 | 2019 | 26 | 0.300 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 628 | 0.300 |
Why?
| | Residence Characteristics | 3 | 2026 | 385 | 0.300 |
Why?
| | Waiting Lists | 1 | 2011 | 251 | 0.290 |
Why?
| | Biomedical Research | 2 | 2020 | 729 | 0.290 |
Why?
| | Data Collection | 3 | 2014 | 650 | 0.290 |
Why?
| | Radiation Oncology | 1 | 2010 | 83 | 0.290 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 217 | 0.290 |
Why?
| | Astrocytoma | 1 | 2010 | 128 | 0.290 |
Why?
| | Physicians | 1 | 2018 | 955 | 0.290 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2016 | 134 | 0.290 |
Why?
| | Recovery of Function | 1 | 2013 | 725 | 0.290 |
Why?
| | Surveys and Questionnaires | 12 | 2018 | 6073 | 0.280 |
Why?
| | Dentists | 1 | 2008 | 21 | 0.280 |
Why?
| | Persuasive Communication | 1 | 2008 | 14 | 0.280 |
Why?
| | Administration, Oral | 2 | 2023 | 872 | 0.280 |
Why?
| | Dental Care | 1 | 2008 | 26 | 0.280 |
Why?
| | Life Expectancy | 1 | 2008 | 72 | 0.270 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2018 | 56 | 0.270 |
Why?
| | Multivariate Analysis | 9 | 2019 | 1543 | 0.270 |
Why?
| | Propensity Score | 1 | 2010 | 376 | 0.270 |
Why?
| | Odds Ratio | 9 | 2014 | 1077 | 0.260 |
Why?
| | Stroke | 3 | 2026 | 1287 | 0.250 |
Why?
| | HIV Infections | 2 | 2022 | 3215 | 0.250 |
Why?
| | Pneumonectomy | 1 | 2008 | 169 | 0.240 |
Why?
| | Patient Education as Topic | 1 | 2011 | 770 | 0.240 |
Why?
| | Likelihood Functions | 5 | 2021 | 138 | 0.240 |
Why?
| | Confidence Intervals | 4 | 2013 | 329 | 0.240 |
Why?
| | Women, Working | 2 | 2002 | 11 | 0.230 |
Why?
| | Quality-Adjusted Life Years | 4 | 2017 | 122 | 0.230 |
Why?
| | Time Factors | 11 | 2013 | 7109 | 0.230 |
Why?
| | Online Systems | 1 | 2005 | 20 | 0.220 |
Why?
| | Depression | 4 | 2021 | 1575 | 0.220 |
Why?
| | Sex Factors | 7 | 2026 | 2107 | 0.220 |
Why?
| | Forecasting | 6 | 2020 | 388 | 0.220 |
Why?
| | Disability Evaluation | 1 | 2007 | 297 | 0.220 |
Why?
| | Colonic Diseases | 2 | 2016 | 39 | 0.220 |
Why?
| | Cost Savings | 2 | 2018 | 87 | 0.220 |
Why?
| | Adolescent | 15 | 2026 | 22557 | 0.220 |
Why?
| | Treatment Outcome | 12 | 2019 | 11821 | 0.210 |
Why?
| | Education, Medical, Graduate | 1 | 2010 | 568 | 0.210 |
Why?
| | Myocardial Infarction | 3 | 2023 | 1215 | 0.210 |
Why?
| | Cross Infection | 2 | 2017 | 258 | 0.210 |
Why?
| | Smoking | 3 | 2026 | 1486 | 0.210 |
Why?
| | Anxiety | 3 | 2021 | 1125 | 0.210 |
Why?
| | Health Services Needs and Demand | 3 | 2017 | 287 | 0.200 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2011 | 702 | 0.200 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 253 | 0.200 |
Why?
| | Models, Statistical | 4 | 2017 | 669 | 0.200 |
Why?
| | Probability | 5 | 2023 | 309 | 0.200 |
Why?
| | Referral and Consultation | 1 | 2010 | 881 | 0.190 |
Why?
| | Needs Assessment | 2 | 2024 | 404 | 0.190 |
Why?
| | Head and Neck Neoplasms | 2 | 2019 | 563 | 0.190 |
Why?
| | Hospitals, Public | 1 | 2023 | 30 | 0.190 |
Why?
| | Physician-Patient Relations | 1 | 2008 | 597 | 0.190 |
Why?
| | Time-to-Treatment | 1 | 2025 | 257 | 0.190 |
Why?
| | Community-Based Participatory Research | 1 | 2024 | 172 | 0.190 |
Why?
| | Substance-Related Disorders | 3 | 1997 | 1100 | 0.190 |
Why?
| | Economics, Medical | 1 | 2022 | 6 | 0.180 |
Why?
| | Staphylococcal Infections | 2 | 2017 | 397 | 0.180 |
Why?
| | Hormones | 1 | 2023 | 134 | 0.180 |
Why?
| | Age Distribution | 4 | 2020 | 399 | 0.180 |
Why?
| | Carcinoma | 2 | 2017 | 225 | 0.180 |
Why?
| | Migraine Disorders | 1 | 2024 | 109 | 0.180 |
Why?
| | Salaries and Fringe Benefits | 1 | 2002 | 57 | 0.180 |
Why?
| | Colonic Polyps | 2 | 2014 | 87 | 0.180 |
Why?
| | Health Behavior | 2 | 2019 | 802 | 0.180 |
Why?
| | Bisexuality | 1 | 2022 | 39 | 0.180 |
Why?
| | Risk Assessment | 6 | 2022 | 3712 | 0.180 |
Why?
| | Hospital Charges | 3 | 2003 | 45 | 0.170 |
Why?
| | Food Supply | 1 | 2022 | 94 | 0.170 |
Why?
| | Proportional Hazards Models | 5 | 2019 | 1331 | 0.170 |
Why?
| | Ambulatory Care Facilities | 1 | 2024 | 269 | 0.170 |
Why?
| | Incidence | 5 | 2022 | 2936 | 0.170 |
Why?
| | Insulin, Isophane | 1 | 2001 | 22 | 0.170 |
Why?
| | Evidence-Based Medicine | 2 | 2016 | 731 | 0.170 |
Why?
| | Hypoglycemic Agents | 3 | 2018 | 1412 | 0.170 |
Why?
| | Intensive Care Units | 2 | 2017 | 925 | 0.160 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 1221 | 0.160 |
Why?
| | Brain Neoplasms | 1 | 2010 | 1325 | 0.160 |
Why?
| | Internet | 1 | 2005 | 660 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 1160 | 0.160 |
Why?
| | Kentucky | 1 | 2020 | 43 | 0.160 |
Why?
| | Exercise | 3 | 2023 | 2213 | 0.160 |
Why?
| | Homosexuality, Male | 1 | 2022 | 231 | 0.160 |
Why?
| | Retrospective Studies | 13 | 2024 | 17438 | 0.160 |
Why?
| | Decision Making | 2 | 2005 | 993 | 0.150 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 102 | 0.150 |
Why?
| | Population Surveillance | 2 | 2022 | 481 | 0.150 |
Why?
| | Sample Size | 1 | 2000 | 124 | 0.150 |
Why?
| | California | 2 | 2018 | 475 | 0.150 |
Why?
| | Regression Analysis | 5 | 2021 | 999 | 0.150 |
Why?
| | Benzodiazepines | 1 | 2021 | 158 | 0.150 |
Why?
| | Carrier State | 2 | 2017 | 80 | 0.150 |
Why?
| | Hospitalization | 5 | 2016 | 2475 | 0.150 |
Why?
| | Stress, Psychological | 2 | 2021 | 1171 | 0.150 |
Why?
| | Language Development Disorders | 1 | 2019 | 40 | 0.140 |
Why?
| | Ownership | 2 | 2010 | 116 | 0.140 |
Why?
| | Infection Control | 2 | 2017 | 174 | 0.140 |
Why?
| | Patient Selection | 3 | 2010 | 728 | 0.140 |
Why?
| | Anthracyclines | 3 | 2023 | 49 | 0.140 |
Why?
| | Los Angeles | 2 | 2015 | 73 | 0.140 |
Why?
| | Feasibility Studies | 1 | 2023 | 1135 | 0.140 |
Why?
| | National Cancer Institute (U.S.) | 3 | 2023 | 56 | 0.140 |
Why?
| | Child | 7 | 2024 | 22693 | 0.140 |
Why?
| | Diabetes Mellitus | 3 | 2018 | 1101 | 0.140 |
Why?
| | Patient Care Team | 1 | 2024 | 701 | 0.140 |
Why?
| | Taxoids | 3 | 2023 | 115 | 0.140 |
Why?
| | Activities of Daily Living | 2 | 2010 | 442 | 0.140 |
Why?
| | Exercise Therapy | 1 | 2023 | 488 | 0.140 |
Why?
| | Cetuximab | 1 | 2018 | 110 | 0.140 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2019 | 222 | 0.130 |
Why?
| | Carboplatin | 1 | 2018 | 168 | 0.130 |
Why?
| | Hyperlipidemias | 1 | 2019 | 120 | 0.130 |
Why?
| | Ireland | 2 | 2016 | 33 | 0.130 |
Why?
| | Cancer Pain | 1 | 2018 | 41 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 449 | 0.130 |
Why?
| | Research Design | 4 | 2007 | 1143 | 0.130 |
Why?
| | Infant, Newborn | 4 | 2020 | 6460 | 0.130 |
Why?
| | Unemployment | 2 | 2009 | 43 | 0.130 |
Why?
| | Hypertension | 2 | 2024 | 1272 | 0.130 |
Why?
| | Managed Care Programs | 1 | 2018 | 137 | 0.130 |
Why?
| | Financing, Government | 1 | 2017 | 53 | 0.130 |
Why?
| | Accidental Falls | 1 | 2020 | 227 | 0.130 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 61 | 0.130 |
Why?
| | Inpatients | 2 | 2012 | 540 | 0.130 |
Why?
| | Public Health Practice | 1 | 2017 | 63 | 0.130 |
Why?
| | Attitude to Health | 3 | 2019 | 421 | 0.130 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1271 | 0.120 |
Why?
| | Patient Rights | 2 | 2019 | 11 | 0.120 |
Why?
| | Psychiatric Department, Hospital | 1 | 1996 | 10 | 0.120 |
Why?
| | Hospital Costs | 2 | 2011 | 131 | 0.120 |
Why?
| | Patient Discharge | 1 | 2023 | 997 | 0.120 |
Why?
| | Cisplatin | 1 | 2018 | 347 | 0.120 |
Why?
| | Sex Distribution | 3 | 2020 | 382 | 0.120 |
Why?
| | Child Behavior | 1 | 1998 | 234 | 0.120 |
Why?
| | Drug Therapy | 1 | 2017 | 85 | 0.120 |
Why?
| | Heart Failure | 2 | 2023 | 2329 | 0.120 |
Why?
| | Language | 1 | 2019 | 315 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2019 | 511 | 0.120 |
Why?
| | Self Efficacy | 1 | 2019 | 418 | 0.110 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2016 | 82 | 0.110 |
Why?
| | Smoking Cessation | 1 | 2019 | 442 | 0.110 |
Why?
| | Neonatal Abstinence Syndrome | 1 | 1996 | 27 | 0.110 |
Why?
| | Clinical Competence | 2 | 2014 | 1272 | 0.110 |
Why?
| | Patient Admission | 1 | 1997 | 216 | 0.110 |
Why?
| | Colorectal Surgery | 1 | 2015 | 32 | 0.110 |
Why?
| | Minority Groups | 1 | 2017 | 286 | 0.110 |
Why?
| | Metformin | 1 | 2018 | 328 | 0.100 |
Why?
| | Case-Control Studies | 4 | 2024 | 3647 | 0.100 |
Why?
| | Child, Preschool | 4 | 2020 | 11913 | 0.100 |
Why?
| | Mastectomy, Segmental | 3 | 2009 | 107 | 0.100 |
Why?
| | Child Development | 1 | 2019 | 481 | 0.100 |
Why?
| | Follow-Up Studies | 6 | 2019 | 5439 | 0.100 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 196 | 0.100 |
Why?
| | National Health Programs | 1 | 2014 | 23 | 0.100 |
Why?
| | Autism Spectrum Disorder | 1 | 2019 | 406 | 0.100 |
Why?
| | Patient Satisfaction | 2 | 2013 | 706 | 0.100 |
Why?
| | Pennsylvania | 2 | 2024 | 136 | 0.100 |
Why?
| | Systems Integration | 1 | 2013 | 36 | 0.100 |
Why?
| | Infant | 3 | 2020 | 10114 | 0.100 |
Why?
| | Bridged-Ring Compounds | 2 | 2023 | 31 | 0.100 |
Why?
| | Health Status Indicators | 1 | 2014 | 167 | 0.100 |
Why?
| | Computer Simulation | 2 | 2023 | 1014 | 0.100 |
Why?
| | Cerebrovascular Disorders | 1 | 2014 | 103 | 0.100 |
Why?
| | Helping Behavior | 1 | 2013 | 20 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 3 | 2021 | 970 | 0.090 |
Why?
| | Pilot Projects | 3 | 2021 | 1888 | 0.090 |
Why?
| | Quality of Health Care | 2 | 2008 | 702 | 0.090 |
Why?
| | Medical Audit | 1 | 2013 | 78 | 0.090 |
Why?
| | Occupations | 1 | 2012 | 50 | 0.090 |
Why?
| | Mandatory Programs | 1 | 2012 | 16 | 0.090 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2012 | 23 | 0.090 |
Why?
| | Pregnancy, Unwanted | 1 | 2012 | 15 | 0.090 |
Why?
| | Maryland | 3 | 1997 | 67 | 0.090 |
Why?
| | Life Tables | 2 | 2008 | 21 | 0.090 |
Why?
| | Intensive Care Units, Neonatal | 1 | 1996 | 295 | 0.090 |
Why?
| | Prospective Studies | 3 | 2017 | 8123 | 0.090 |
Why?
| | Cost Control | 1 | 2012 | 38 | 0.090 |
Why?
| | Cause of Death | 1 | 2014 | 456 | 0.090 |
Why?
| | Goals | 2 | 2023 | 187 | 0.090 |
Why?
| | Self Disclosure | 1 | 2011 | 62 | 0.090 |
Why?
| | Community Health Services | 1 | 2013 | 229 | 0.090 |
Why?
| | Contraceptive Agents, Female | 1 | 2012 | 80 | 0.080 |
Why?
| | Contraception Behavior | 1 | 2012 | 108 | 0.080 |
Why?
| | Educational Status | 1 | 2013 | 466 | 0.080 |
Why?
| | Retreatment | 1 | 2011 | 79 | 0.080 |
Why?
| | Sepsis | 1 | 2017 | 669 | 0.080 |
Why?
| | Video Recording | 1 | 2011 | 219 | 0.080 |
Why?
| | Mental Disorders | 2 | 1997 | 1148 | 0.080 |
Why?
| | Economics, Nursing | 1 | 2010 | 1 | 0.080 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 56 | 0.080 |
Why?
| | Stress, Physiological | 1 | 2013 | 450 | 0.080 |
Why?
| | Insulin | 1 | 2001 | 2525 | 0.080 |
Why?
| | Access to Information | 1 | 2010 | 46 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2014 | 594 | 0.080 |
Why?
| | Mastectomy | 1 | 2011 | 189 | 0.080 |
Why?
| | Pregnancy Complications | 1 | 1996 | 609 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2010 | 3416 | 0.080 |
Why?
| | Consumer Behavior | 1 | 1990 | 68 | 0.080 |
Why?
| | Sentinel Surveillance | 1 | 2009 | 48 | 0.080 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 301 | 0.070 |
Why?
| | Standard of Care | 1 | 2010 | 81 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2013 | 561 | 0.070 |
Why?
| | Insurance Claim Reporting | 1 | 2009 | 25 | 0.070 |
Why?
| | Ohio | 1 | 2009 | 136 | 0.070 |
Why?
| | Occult Blood | 1 | 2009 | 41 | 0.070 |
Why?
| | Private Sector | 1 | 2009 | 50 | 0.070 |
Why?
| | Women's Health | 2 | 2012 | 317 | 0.070 |
Why?
| | Physical Exertion | 1 | 2010 | 204 | 0.070 |
Why?
| | Comparative Effectiveness Research | 1 | 2010 | 171 | 0.070 |
Why?
| | Bias | 1 | 2010 | 197 | 0.070 |
Why?
| | Linear Models | 1 | 2011 | 857 | 0.070 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2009 | 74 | 0.070 |
Why?
| | Home Nursing | 1 | 2008 | 24 | 0.070 |
Why?
| | Psychometrics | 1 | 2013 | 712 | 0.070 |
Why?
| | Reimbursement Mechanisms | 1 | 2009 | 79 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2026 | 2921 | 0.070 |
Why?
| | Prevalence | 2 | 2020 | 2861 | 0.070 |
Why?
| | Sex Characteristics | 2 | 2022 | 801 | 0.070 |
Why?
| | Education, Professional | 1 | 2008 | 18 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 368 | 0.070 |
Why?
| | Health Care Surveys | 1 | 2010 | 541 | 0.070 |
Why?
| | Pain | 2 | 2010 | 790 | 0.060 |
Why?
| | Radiotherapy | 1 | 2008 | 209 | 0.060 |
Why?
| | Self Care | 1 | 2010 | 396 | 0.060 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 517 | 0.060 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 928 | 0.060 |
Why?
| | Leukemia | 1 | 2008 | 246 | 0.060 |
Why?
| | Protective Factors | 1 | 2026 | 97 | 0.060 |
Why?
| | Cognition Disorders | 1 | 2010 | 559 | 0.060 |
Why?
| | Lung Diseases | 1 | 2012 | 787 | 0.060 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2006 | 147 | 0.060 |
Why?
| | Charities | 1 | 2005 | 12 | 0.060 |
Why?
| | Empirical Research | 1 | 2005 | 21 | 0.050 |
Why?
| | Hospice Care | 1 | 2007 | 230 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2001 | 3930 | 0.050 |
Why?
| | Diagnosis-Related Groups | 1 | 2003 | 34 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 1763 | 0.050 |
Why?
| | Resource Allocation | 1 | 2003 | 45 | 0.050 |
Why?
| | Florida | 2 | 2014 | 117 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1707 | 0.050 |
Why?
| | Health Surveys | 2 | 2007 | 511 | 0.050 |
Why?
| | Causality | 1 | 2023 | 128 | 0.050 |
Why?
| | Social Security | 1 | 2002 | 5 | 0.050 |
Why?
| | Selection Bias | 1 | 2002 | 38 | 0.050 |
Why?
| | Markov Chains | 2 | 2017 | 129 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 704 | 0.050 |
Why?
| | Sampling Studies | 1 | 2002 | 97 | 0.040 |
Why?
| | Mastectomy, Radical | 1 | 2001 | 4 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2002 | 109 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2005 | 930 | 0.040 |
Why?
| | Insulin, Long-Acting | 1 | 2001 | 65 | 0.040 |
Why?
| | Family Characteristics | 1 | 2002 | 203 | 0.040 |
Why?
| | Arrhythmias, Cardiac | 1 | 2023 | 358 | 0.040 |
Why?
| | Insulin Glargine | 1 | 2001 | 88 | 0.040 |
Why?
| | Normal Distribution | 1 | 2000 | 22 | 0.040 |
Why?
| | Drug Evaluation | 1 | 2000 | 78 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 944 | 0.040 |
Why?
| | Diffusion of Innovation | 1 | 2001 | 96 | 0.040 |
Why?
| | Nursing Research | 1 | 2000 | 49 | 0.040 |
Why?
| | Presenteeism | 1 | 2019 | 6 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 1064 | 0.040 |
Why?
| | Palliative Care | 1 | 2007 | 1032 | 0.040 |
Why?
| | Etidronic Acid | 1 | 1998 | 3 | 0.040 |
Why?
| | Alendronate | 1 | 1998 | 14 | 0.040 |
Why?
| | Federal Government | 1 | 2018 | 23 | 0.040 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 1998 | 41 | 0.030 |
Why?
| | Informed Consent | 1 | 2000 | 195 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 406 | 0.030 |
Why?
| | Ecosystem | 1 | 2022 | 483 | 0.030 |
Why?
| | Algorithms | 1 | 2026 | 1849 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 15 | 0.030 |
Why?
| | Spinal Fractures | 1 | 1998 | 81 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2019 | 174 | 0.030 |
Why?
| | Smoking Prevention | 1 | 1998 | 168 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2019 | 335 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 1998 | 144 | 0.030 |
Why?
| | Tennessee | 1 | 2017 | 57 | 0.030 |
Why?
| | Hyperglycemia | 1 | 2001 | 384 | 0.030 |
Why?
| | Puberty | 1 | 1998 | 141 | 0.030 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 1997 | 38 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2018 | 238 | 0.030 |
Why?
| | Patient Isolation | 1 | 2017 | 20 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2017 | 183 | 0.030 |
Why?
| | Utilization Review | 1 | 1996 | 39 | 0.030 |
Why?
| | Schools | 1 | 2000 | 436 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 790 | 0.030 |
Why?
| | Arizona | 1 | 1996 | 81 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 66 | 0.030 |
Why?
| | Anticholesteremic Agents | 1 | 2018 | 156 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 70 | 0.030 |
Why?
| | Patient Dropouts | 1 | 1997 | 65 | 0.030 |
Why?
| | Catheter-Related Infections | 1 | 2017 | 101 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2018 | 184 | 0.030 |
Why?
| | Health Policy | 1 | 2019 | 399 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2002 | 641 | 0.030 |
Why?
| | Hospitals, Community | 1 | 1996 | 68 | 0.030 |
Why?
| | Obstetric Labor, Premature | 1 | 1996 | 39 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 504 | 0.030 |
Why?
| | Health Resources | 2 | 2009 | 131 | 0.030 |
Why?
| | Protoporphyrins | 1 | 1993 | 16 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 519 | 0.030 |
Why?
| | Telemedicine | 1 | 2023 | 966 | 0.020 |
Why?
| | Learning Curve | 1 | 2014 | 71 | 0.020 |
Why?
| | Acute Disease | 1 | 1996 | 1038 | 0.020 |
Why?
| | Lead | 1 | 1993 | 71 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1712 | 0.020 |
Why?
| | Obesity | 1 | 2026 | 3131 | 0.020 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 1998 | 0.020 |
Why?
| | Calcium | 1 | 1998 | 1181 | 0.020 |
Why?
| | Community Participation | 1 | 2013 | 128 | 0.020 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 634 | 0.020 |
Why?
| | Societies, Medical | 1 | 2016 | 907 | 0.020 |
Why?
| | Risk | 1 | 2014 | 920 | 0.020 |
Why?
| | Gastroenterology | 1 | 2014 | 187 | 0.020 |
Why?
| | General Surgery | 1 | 2014 | 217 | 0.020 |
Why?
| | Pregnancy | 2 | 2012 | 7230 | 0.020 |
Why?
| | Hepatitis B | 1 | 1991 | 66 | 0.020 |
Why?
| | Work Capacity Evaluation | 1 | 2010 | 10 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 471 | 0.020 |
Why?
| | Contraception | 1 | 2012 | 170 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4351 | 0.020 |
Why?
| | Budgets | 1 | 2009 | 14 | 0.020 |
Why?
| | Sigmoidoscopy | 1 | 2009 | 14 | 0.020 |
Why?
| | Leadership | 1 | 2013 | 414 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2010 | 203 | 0.020 |
Why?
| | Prostatectomy | 1 | 2009 | 93 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2009 | 173 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2013 | 628 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 558 | 0.020 |
Why?
| | Occupational Exposure | 1 | 1991 | 356 | 0.020 |
Why?
| | Psychology | 1 | 2008 | 85 | 0.020 |
Why?
| | Demography | 1 | 2008 | 274 | 0.020 |
Why?
| | Least-Squares Analysis | 1 | 2006 | 73 | 0.010 |
Why?
| | Lifting | 1 | 2006 | 4 | 0.010 |
Why?
| | Illinois | 1 | 2006 | 47 | 0.010 |
Why?
| | Mortality | 1 | 2008 | 375 | 0.010 |
Why?
| | Body Weight | 1 | 1990 | 968 | 0.010 |
Why?
| | Telephone | 1 | 2007 | 175 | 0.010 |
Why?
| | Prejudice | 1 | 2006 | 60 | 0.010 |
Why?
| | Patient Compliance | 1 | 2009 | 589 | 0.010 |
Why?
| | Myocardial Revascularization | 1 | 2003 | 85 | 0.010 |
Why?
| | Burnout, Professional | 1 | 2010 | 493 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 426 | 0.010 |
Why?
| | Vaccination | 1 | 1991 | 1449 | 0.010 |
Why?
| | Behavior | 1 | 2002 | 90 | 0.010 |
Why?
| | Episode of Care | 1 | 2001 | 7 | 0.010 |
Why?
| | Decision Trees | 1 | 2001 | 76 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2002 | 314 | 0.010 |
Why?
| | Cardiac Catheterization | 1 | 2003 | 571 | 0.010 |
Why?
| | Reoperation | 1 | 2001 | 645 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2002 | 1149 | 0.010 |
Why?
| | Estrogens | 1 | 1998 | 364 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 1998 | 1036 | 0.010 |
Why?
| | Estradiol | 1 | 1998 | 517 | 0.010 |
Why?
| | Lead Poisoning | 1 | 1993 | 18 | 0.010 |
Why?
| | Reference Values | 1 | 1993 | 796 | 0.010 |
Why?
| | ROC Curve | 1 | 1993 | 617 | 0.010 |
Why?
| | Program Evaluation | 1 | 1991 | 952 | 0.000 |
Why?
|
|
Bradley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|